- Home
- PD vs ADPT Comparison
PD vs ADPT Comparison
Compare PD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- ADPT
- Stock Information
- Founded
- PD 2009
- ADPT 2009
- Country
- PD United States
- ADPT United States
- Employees
- PD N/A
- ADPT N/A
- Industry
- PD Computer Software: Prepackaged Software
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PD Technology
- ADPT Health Care
- Exchange
- PD Nasdaq
- ADPT Nasdaq
- Market Cap
- PD 1.5B
- ADPT 1.8B
- IPO Year
- PD 2019
- ADPT 2019
- Fundamental
- Price
- PD $16.41
- ADPT $13.77
- Analyst Decision
- PD Hold
- ADPT Strong Buy
- Analyst Count
- PD 9
- ADPT 8
- Target Price
- PD $18.33
- ADPT $12.38
- AVG Volume (30 Days)
- PD 2.5M
- ADPT 1.7M
- Earning Date
- PD 09-03-2025
- ADPT 11-06-2025
- Dividend Yield
- PD N/A
- ADPT N/A
- EPS Growth
- PD N/A
- ADPT N/A
- EPS
- PD N/A
- ADPT N/A
- Revenue
- PD $483,608,000.00
- ADPT $205,216,000.00
- Revenue This Year
- PD $9.16
- ADPT $32.76
- Revenue Next Year
- PD $6.79
- ADPT $15.81
- P/E Ratio
- PD N/A
- ADPT N/A
- Revenue Growth
- PD 8.20
- ADPT 21.60
- 52 Week Low
- PD $13.70
- ADPT $3.98
- 52 Week High
- PD $21.98
- ADPT $13.78
- Technical
- Relative Strength Index (RSI)
- PD 52.34
- ADPT 61.65
- Support Level
- PD $15.74
- ADPT $12.59
- Resistance Level
- PD $16.68
- ADPT $13.68
- Average True Range (ATR)
- PD 0.79
- ADPT 0.67
- MACD
- PD -0.07
- ADPT -0.01
- Stochastic Oscillator
- PD 69.55
- ADPT 98.62
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).